What is the pathophysiology and management of critical illness‑related corticosteroid insufficiency (CIRCI)?

Critical Illness-Related Corticosteroid Insufficiency (CIRCI): Pathophysiology and Management

CIRCI is a state of dysregulated systemic inflammation resulting from inadequate intracellular glucocorticoid-mediated anti-inflammatory activity relative to the severity of critical illness, and should be treated with IV hydrocortisone <400 mg/day for ≥3 days in patients with septic shock unresponsive to fluids and moderate-to-high-dose vasopressors. 1

Pathophysiology

CIRCI involves three interconnected pathophysiologic mechanisms that distinguish it from classic adrenal insufficiency 2:

1. Dysregulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis

The HPA axis dysfunction in CIRCI is complex, involving multidirectional crosstalk between CRH/ACTH pathways, the autonomic nervous system, vasopressinergic system, and immune system. This is not simply reduced cortisol production—it's a failure of the normal regulatory feedback mechanisms 2.

2. Altered Cortisol Metabolism

Plasma clearance of cortisol is markedly reduced during critical illness due to suppressed expression and activity of primary cortisol-metabolizing enzymes in the liver and kidney. This paradoxically results in elevated cortisol levels that are still insufficient for the degree of illness 2.

3. Tissue Glucocorticoid Resistance

Despite elevated circulating cortisol levels, tissues demonstrate resistance to glucocorticoids, resulting in insufficient glucocorticoid alpha-mediated anti-inflammatory activity. This explains why patients can have "normal" or even elevated cortisol levels yet still benefit from exogenous corticosteroids 1, 2.

Clinical Presentation

Key clinical features to identify 1:

Cardiovascular:

• Hypotension refractory to fluid resuscitation
• Decreased sensitivity to catecholamines (requiring escalating vasopressor doses)
• High cardiac index despite shock

Neurological:

• Confusion, delirium, or coma

Laboratory:

• Hypoglycemia
• Hyponatremia
• Hyperkalemia
• Metabolic acidosis

Respiratory:

• Persistent hypoxia

Other:

• Fever, intolerance to enteral nutrition, nausea/vomiting

Diagnosis

The task force could not agree on a single reliable diagnostic test for CIRCI 1. However, two approaches may be used clinically:

1. Delta cortisol <9 μg/dL at 60 minutes after cosyntropin 250 μg administration
2. Random plasma cortisol <10 μg/dL

Important caveats:

• Do NOT use plasma free cortisol or salivary cortisol over plasma total cortisol 1
• The Surviving Sepsis Campaign guidelines suggest NOT using ACTH stimulation testing to select patients for hydrocortisone treatment 1
• Diagnosis should be based primarily on clinical presentation rather than biochemical testing alone

Management: Condition-Specific Algorithms

Septic Shock (Fluid and Vasopressor-Refractory)

Use IV hydrocortisone <400 mg/day for ≥3 days at full dose in patients with septic shock not responsive to fluid resuscitation and requiring moderate-to-high-dose vasopressor therapy 1.

Do NOT use corticosteroids in adult patients with sepsis without shock 1.

Rationale: This targets the specific population most likely to benefit—those with vasopressor-dependent shock where CIRCI contributes to catecholamine resistance.

Acute Respiratory Distress Syndrome (ARDS)

Use IV methylprednisolone 1 mg/kg/day in patients with:

• Early moderate to severe ARDS (PaO₂/FiO₂ <200)
• Within 14 days of ARDS onset 1

Critical timing: Must be initiated within the 14-day window; late administration may be harmful.

Major Trauma

Do NOT use corticosteroids in patients with major trauma 1.

Cardiac Arrest

Use corticosteroids during cardiac arrest resuscitation 3. Studies show:

• Improved return of spontaneous circulation (OR 2.98)
• Better survival to hospital discharge with good neurological outcome (OR 3.28 with methylprednisolone during resuscitation; OR 3.74 with hydrocortisone for post-resuscitation shock)

Cardiopulmonary Bypass Surgery

Use perioperative corticosteroids in adults undergoing cardiopulmonary bypass 3.

Practical Implementation

Dosing specifics:

• Hydrocortisone: <400 mg/day IV (typically 50 mg IV every 6 hours or 200 mg/day continuous infusion)
• Methylprednisolone: 1 mg/kg/day IV for ARDS
• Duration: Minimum 3 days at full dose for septic shock

Tapering strategy:

• Do not abruptly discontinue
• Taper once vasopressors are weaned and shock has resolved
• Monitor for recurrence of shock during taper

Common Pitfalls

1. Using corticosteroids in sepsis without shock: This provides no mortality benefit and exposes patients to unnecessary risks 1.

2. Delaying treatment while awaiting cortisol results: Clinical presentation should drive treatment decisions in vasopressor-refractory shock, not laboratory confirmation 1.

3. Using ACTH stimulation testing to select patients: Current guidelines recommend against this practice in septic shock 1.

4. Administering corticosteroids late in ARDS: The 14-day window is critical; late administration may worsen outcomes 1.

5. Assuming elevated cortisol excludes CIRCI: Tissue resistance means patients with "adequate" cortisol levels may still benefit from exogenous corticosteroids 2.

Monitoring During Therapy

Essential monitoring parameters:

• Hemodynamic response (vasopressor requirements)
• Blood glucose (hyperglycemia is common)
• Electrolytes (hypokalemia risk)
• Signs of secondary infection
• Gastrointestinal bleeding risk
• Neuropsychiatric effects

The evidence base for CIRCI management remains conditional with low-to-moderate quality evidence across most recommendations 1. The pathophysiology is complex and incompletely understood, making empiric treatment based on clinical syndrome more reliable than biochemical diagnosis. The key is matching the right corticosteroid regimen to the specific critical illness syndrome rather than applying a uniform approach.